Marimastat (BB2516) | MMP Inhibitor

Size	Price	VIP Price	US Stock	Global Stock	In Stock
{[ item.pr_size ]}		Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

CAS No. :	154039-60-8
Formula :	C₁₅H₂₉N₃O₅
M.W :	331.41
SMILES Code :	O=C(N[C@@H](C(C)(C)C)C(NC)=O)[C@H](CC(C)C)[C@H](O)C(NO)=O
Synonyms :	BB2516; TA2516; KB-R8898
MDL No. :	MFCD00866242
InChI Key :	OCSMOTCMPXTDND-OUAUKWLOSA-N
Pubchem ID :	119031

GHS Pictogram:
Signal Word:	Warning
Hazard Statements:	H302-H315-H319-H335
Precautionary Statements:	P261-P305+P351+P338

Polycystic kidney (PCK) rat cholangiocytes	200 μM	24 hours	Inhibition of cystic expansion in polycystic kidney (PCK) cholangiocytes	PMC4362729
HaCaT cells	2.56 µM	24 hours	To test the inhibitory effect of Marimastat on venom-induced cytotoxicity, results showed that Marimastat significantly reduced the cell-damaging potency of certain snake venoms.	PMC10721902
4T1 cells	5 μg/mL	24 hours	HPMC NPs significantly downregulated the expressions of MMP-2, MMP-3, MMP-7, and MMP-9 by 100-300%, and inhibited the activities of MMP-9 and MMP-7 by 50-100%.	PMC5957012
786-O cells	1 μM, 2 μM, 3 μM	24 hours	Marimastat could more efficiently reduce renal cell proliferation and invasive capacity, and increase the apoptosis rate of 786-O cells.	PMC3662624
OS-RC-2 cells	1 μM, 2 μM, 3 μM	24 hours	Marimastat could more efficiently reduce renal cell proliferation and invasive capacity.	PMC3662624
ECFCs	10 µM	24 hours	To evaluate the effect of Marimastat on cell viability and invasion ability of ECFCs. Results showed that Marimastat promoted ECFC invasion and tubular formation, inducing amoeboid characteristics.	PMC9912547
Crotalus atrox venom proteins	15 μM and 150 μM	30 minutes	To assess the stabilizing effect of Marimastat on SVMP proteins in Crotalus atrox venom. Results showed that Marimastat significantly increased the stability of SVMP proteins in solution and reduced their content in the precipitate.	PMC11154231
mouse cerebrovascular endothelial cells (mCEC)	5% v/v	4 hours	To assess the inflammatory bioactivity of serum following MWCNT exposure, results showed that MWCNT exposure significantly upregulated endothelial Ccl2 and Vcam1 mRNA, while Marimastat pretreatment partially inhibited these effects.	PMC8424988
4T1 cells	5 µg/mL	48 hours	To evaluate the cytotoxicity of MATT-LTSLs on 4T1 cells, results showed that at 5 μg/mL, MATT-LTSLs did not significantly affect cell viability.	PMC6799847
MDA-MB-435 cells	10 µg/mL	48 hours	To evaluate the cytotoxicity of MATT-LTSLs on MDA-MB-435 cells, results showed that at 10 μg/mL, MATT-LTSLs did not significantly affect cell viability.	PMC6799847
zebrafish embryos	50 µM	48 hours	Screening compounds that can reduce scleral tissue expansion, Marimastat significantly reduced the percentage of scleral tissue expansion	PMC7941086
HRECs	10 µM	48 hours	To evaluate the effect of Marimastat on migration and tubular formation of HRECs. Results showed that Marimastat slightly inhibited the differentiation of HRECs in tubular structures and didn’t affect the migration ability without stimulating it.	PMC9912547
U87	200 nM	5 days	To evaluate the effect of Marimastat on TMZ resistance, results showed Marimastat did not significantly enhance TMZ sensitivity	PMC4648299
GBM29	200 nM	5 days	To evaluate the effect of Marimastat on TMZ resistance, results showed Marimastat did not significantly enhance TMZ sensitivity	PMC4648299
GBM42	200 nM	5 days	To evaluate the effect of Marimastat on TMZ resistance, results showed Marimastat did not significantly enhance TMZ sensitivity	PMC4648299
GBM98	200 nM	5 days	To evaluate the effect of Marimastat on TMZ resistance, results showed Marimastat did not significantly enhance TMZ sensitivity	PMC4648299
Normal human cholangiocytes	200 μM		Inhibition of matrix metalloprotease (MMP) activity	PMC4362729
Polycystic human cholangiocytes	200 μM		Inhibition of matrix metalloprotease (MMP) activity	PMC4362729

Polycystic kidney (PCK) rats	Polycystic kidney (PCK) rat model	Oral	0.2856 mg/kg/day	Twice daily for 8 weeks	Inhibition of hepatic cystogenesis and fibrosis	PMC4362729
Mice	4T1 tumor model	tail vein injection	5 mg/kg	every 3 days for 18 days	To evaluate the antitumor efficacy of MATT-LTSLs in 4T1 tumor-bearing mice, results showed that MATT-LTSLs significantly inhibited tumor growth and reduced the number of metastatic lung nodules and microvessels inside the tumor.	PMC6799847
Mice	Dermonecrosis model	Intradermal injection	60 µg	Single injection, lasting 72 hours	To test the inhibitory effect of Marimastat on venom-induced dermonecrosis, results showed that Marimastat significantly reduced the area of skin lesions.	PMC10721902
Mice	Snake envenoming model	Intravenous injection	60 µg/mouse	Single dose, monitored for 6 hours	Marimastat significantly prolonged the survival time of envenomed mice, with only one mouse succumbing at the end of the 6-hour experimental period, while the remaining four survived.	PMC7738508
C57BL6 mice	Colorectal cancer model	Intraperitoneal injection	15 mg/kg	Daily for 15 days	Marimastat treatment reduced tumor size, with enhanced effects when combined with miR-126 overexpression.	PMC11487245
Balb/C mice	4T1 breast cancer model	intravenous injection	5 mg/kg	Every 3 days for 15 days	HPMC NPs significantly inhibited tumor growth, reducing tumor volume by 5.5-fold, and significantly downregulated the expressions and activities of MMP-2 and MMP-9 by >150% and >50%, respectively.	PMC5957012
C57BL/6 mice	form-deprivation myopia model	eye drops	50 µM	twice daily for 28 days	Validate the efficacy of Marimastat in form-deprivation myopia models, results showed Marimastat significantly mitigated myopic shift and axial elongation	PMC7941086
A/J mice	AOM-induced colon cancer model	Alzet pump implantation	1.1 μmoles/day/mouse	Daily administration for 2 weeks	To assess the effect of Marimastat on EGFR signaling in the colonic mucosa of mice fed a Western diet (WD), results showed that Marimastat significantly inhibited EGFR signals in the colonic mucosa, with greater than 50% reductions in phospho-active EGFR (pEGFR), pErbB2 and pERK.	PMC5241244
C57BL/6 mice	MWCNT-induced pulmonary inflammation model	oropharyngeal aspiration	10 mg/kg body weight	single dose, 24 hours duration	To investigate the effect of Marimastat on MWCNT-induced pulmonary inflammation and serum peptide generation, results showed that Marimastat significantly inhibited MWCNT-induced serum peptide generation but had minimal effect on pulmonary inflammation.	PMC8424988
SCID beige mice	Matrigel plug assay	Subcutaneous injection	50 µM	Single injection, lasting 5 days	To evaluate the effect of Marimastat on angiogenesis in mice. Results showed that Marimastat stimulated angiogenesis.	PMC9912547

{[proInfo.proName]}

CAS No.: 154039-60-8

{[proInfo.proName]}

CAS No.: 154039-60-8

Alternative Products

Product Details of Marimastat

Safety of Marimastat

Isoform Comparison

Biological Activity

Protocol

References

Historical Records

Categories

Precautionary Statements-General

Prevention

Response

Storage

Disposal

Physical hazards

Health hazards

Environmental hazards

Inquiry

Molarity Calculator

Total Compounds Calculator

Dissolution Calculator

NCT00261391	Vascular Anomalies	PHASE1	COMPLETED	2025-10-07	Childrens Hospital, Boston, Ma... More >>ssachusetts, 02115, United States Less <<
NCT00002911	Lung Cancer	Phase 3	Completed	-	-
NCT00003010	Breast Cancer	Phase 3	Completed	-	United States, Arizona ... More >> CCOP - Scottsdale Oncology Program Scottsdale, Arizona, United States, 85259-5404 United States, Illinois Robert H. Lurie Comprehensive Cancer Center, Northwestern University Chicago, Illinois, United States, 60611 CCOP - Carle Cancer Center Urbana, Illinois, United States, 61801 United States, Iowa CCOP - Cedar Rapids Oncology Project Cedar Rapids, Iowa, United States, 52403-1206 CCOP - Iowa Oncology Research Association Des Moines, Iowa, United States, 50309-1016 Siouxland Hematology-Oncology Sioux City, Iowa, United States, 51101-1733 United States, Kansas CCOP - Wichita Wichita, Kansas, United States, 67214-3882 United States, Minnesota CCOP - Duluth Duluth, Minnesota, United States, 55805 Mayo Clinic Cancer Center Rochester, Minnesota, United States, 55905 CentraCare Clinic Saint Cloud, Minnesota, United States, 56303 United States, Nebraska CCOP - Missouri Valley Cancer Consortium Omaha, Nebraska, United States, 68131 United States, New Jersey Trinitas Hospital - Jersey Street Campus Elizabeth, New Jersey, United States, 07201 Hunterdon Regional Cancer Center Flemington, New Jersey, United States, 08822 Hackensack University Medical Center Hackensack, New Jersey, United States, 07601 Morristown Memorial Hospital Morristown, New Jersey, United States, 07962-1956 Riverview Medical Center Red Bank, New Jersey, United States, 07701 St. Francis Medical Center Trenton, New Jersey, United States, 08629 United States, New York Albert Einstein Comprehensive Cancer Center Bronx, New York, United States, 10461 United States, North Dakota Medcenter One Health System Bismarck, North Dakota, United States, 58501 Altru Health Systems Grand Forks, North Dakota, United States, 58201 United States, Ohio CCOP - Columbus Columbus, Ohio, United States, 43206 CCOP - Toledo Community Hospital Oncology Program Toledo, Ohio, United States, 43623-3456 United States, Pennsylvania Hahnemann University Hospital Philadelphia, Pennsylvania, United States, 19102-1192 United States, South Dakota Rapid City Regional Hospital Rapid City, South Dakota, United States, 57709 CCOP - Sioux Community Cancer Consortium Sioux Falls, South Dakota, United States, 57105-1080 Less <<
NCT00003011	Lung Cancer	Phase 3	Completed	-	-

Bio Calculators
Preparing Stock Solutions		1mg	5mg	10mg
Preparing Stock Solutions	1 mM 5 mM 10 mM	3.02mL 0.60mL 0.30mL	15.09mL 3.02mL 1.51mL	30.17mL 6.03mL 3.02mL
Dissolving Methods	Animal experiment Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn: in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day; The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound. Protocol 1 Protocol 2

Precautionary Statements-General
Code	Phrase
P101	If medical advice is needed,have product container or label at hand.
P102	Keep out of reach of children.
P103	Read label before use
Prevention
Code	Phrase
P201	Obtain special instructions before use.
P202	Do not handle until all safety precautions have been read and understood.
P210	Keep away from heat/sparks/open flames/hot surfaces. - No smoking.
P211	Do not spray on an open flame or other ignition source.
P220	Keep/Store away from clothing/combustible materials.
P221	Take any precaution to avoid mixing with combustibles
P222	Do not allow contact with air.
P223	Keep away from any possible contact with water, because of violent reaction and possible flash fire.
P230	Keep wetted
P231	Handle under inert gas.
P232	Protect from moisture.
P233	Keep container tightly closed.
P234	Keep only in original container.
P235	Keep cool
P240	Ground/bond container and receiving equipment.
P241	Use explosion-proof electrical/ventilating/lighting/equipment.
P242	Use only non-sparking tools.
P243	Take precautionary measures against static discharge.
P244	Keep reduction valves free from grease and oil.
P250	Do not subject to grinding/shock/friction.
P251	Pressurized container: Do not pierce or burn, even after use.
P260	Do not breathe dust/fume/gas/mist/vapours/spray.
P261	Avoid breathing dust/fume/gas/mist/vapours/spray.
P262	Do not get in eyes, on skin, or on clothing.
P263	Avoid contact during pregnancy/while nursing.
P264	Wash hands thoroughly after handling.
P265	Wash skin thouroughly after handling.
P270	Do not eat, drink or smoke when using this product.
P271	Use only outdoors or in a well-ventilated area.
P272	Contaminated work clothing should not be allowed out of the workplace.
P273	Avoid release to the environment.
P280	Wear protective gloves/protective clothing/eye protection/face protection.
P281	Use personal protective equipment as required.
P282	Wear cold insulating gloves/face shield/eye protection.
P283	Wear fire/flame resistant/retardant clothing.
P284	Wear respiratory protection.
P285	In case of inadequate ventilation wear respiratory protection.
P231 + P232	Handle under inert gas. Protect from moisture.
P235 + P410	Keep cool. Protect from sunlight.
Response
Code	Phrase
P301	IF SWALLOWED:
P304	IF INHALED:
P305	IF IN EYES:
P306	IF ON CLOTHING:
P307	IF exposed:
P308	IF exposed or concerned:
P309	IF exposed or if you feel unwell:
P310	Immediately call a POISON CENTER or doctor/physician.
P311	Call a POISON CENTER or doctor/physician.
P312	Call a POISON CENTER or doctor/physician if you feel unwell.
P313	Get medical advice/attention.
P314	Get medical advice/attention if you feel unwell.
P315	Get immediate medical advice/attention.
P320
P302 + P352	IF ON SKIN: wash with plenty of soap and water.
P321
P322
P330	Rinse mouth.
P331	Do NOT induce vomiting.
P332	IF SKIN irritation occurs:
P333	If skin irritation or rash occurs:
P334	Immerse in cool water/wrap n wet bandages.
P335	Brush off loose particles from skin.
P336	Thaw frosted parts with lukewarm water. Do not rub affected area.
P337	If eye irritation persists:
P338	Remove contact lenses, if present and easy to do. Continue rinsing.
P340	Remove victim to fresh air and keep at rest in a position comfortable for breathing.
P341	If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P342	If experiencing respiratory symptoms:
P350	Gently wash with plenty of soap and water.
P351	Rinse cautiously with water for several minutes.
P352	Wash with plenty of soap and water.
P353	Rinse skin with water/shower.
P360	Rinse immediately contaminated clothing and skin with plenty of water before removing clothes.
P361	Remove/Take off immediately all contaminated clothing.
P362	Take off contaminated clothing and wash before reuse.
P363	Wash contaminated clothing before reuse.
P370	In case of fire:
P371	In case of major fire and large quantities:
P372	Explosion risk in case of fire.
P373	DO NOT fight fire when fire reaches explosives.
P374	Fight fire with normal precautions from a reasonable distance.
P376	Stop leak if safe to do so. Oxidising gases (section 2.4) 1
P377	Leaking gas fire: Do not extinguish, unless leak can be stopped safely.
P378
P380	Evacuate area.
P381	Eliminate all ignition sources if safe to do so.
P390	Absorb spillage to prevent material damage.
P391	Collect spillage. Hazardous to the aquatic environment
P301 + P310	IF SWALLOWED: Immediately call a POISON CENTER or doctor/physician.
P301 + P312	IF SWALLOWED: call a POISON CENTER or doctor/physician IF you feel unwell.
P301 + P330 + P331	IF SWALLOWED: Rinse mouth. Do NOT induce vomiting.
P302 + P334	IF ON SKIN: Immerse in cool water/wrap in wet bandages.
P302 + P350	IF ON SKIN: Gently wash with plenty of soap and water.
P303 + P361 + P353	IF ON SKIN (or hair): Remove/Take off Immediately all contaminated clothing. Rinse SKIN with water/shower.
P304 + P312	IF INHALED: Call a POISON CENTER or doctor/physician if you feel unwell.
P304 + P340	IF INHALED: Remove victim to fresh air and Keep at rest in a position comfortable for breathing.
P304 + P341	IF INHALED: If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P305 + P351 + P338	IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.
P306 + P360	IF ON CLOTHING: Rinse Immediately contaminated CLOTHING and SKIN with plenty of water before removing clothes.
P307 + P311	IF exposed: call a POISON CENTER or doctor/physician.
P308 + P313	IF exposed or concerned: Get medical advice/attention.
P309 + P311	IF exposed or if you feel unwell: call a POISON CENTER or doctor/physician.
P332 + P313	IF SKIN irritation occurs: Get medical advice/attention.
P333 + P313	IF SKIN irritation or rash occurs: Get medical advice/attention.
P335 + P334	Brush off loose particles from skin. Immerse in cool water/wrap in wet bandages.
P337 + P313	IF eye irritation persists: Get medical advice/attention.
P342 + P311	IF experiencing respiratory symptoms: call a POISON CENTER or doctor/physician.
P370 + P376	In case of fire: Stop leak if safe to Do so.
P370 + P378	In case of fire:
P370 + P380	In case of fire: Evacuate area.
P370 + P380 + P375	In case of fire: Evacuate area. Fight fire remotely due to the risk of explosion.
P371 + P380 + P375	In case of major fire and large quantities: Evacuate area. Fight fire remotely due to the risk of explosion.
Storage
Code	Phrase
P401
P402	Store in a dry place.
P403	Store in a well-ventilated place.
P404	Store in a closed container.
P405	Store locked up.
P406	Store in corrosive resistant/ container with a resistant inner liner.
P407	Maintain air gap between stacks/pallets.
P410	Protect from sunlight.
P411
P412	Do not expose to temperatures exceeding 50 oC/ 122 oF.
P413
P420	Store away from other materials.
P422
P402 + P404	Store in a dry place. Store in a closed container.
P403 + P233	Store in a well-ventilated place. Keep container tightly closed.
P403 + P235	Store in a well-ventilated place. Keep cool.
P410 + P403	Protect from sunlight. Store in a well-ventilated place.
P410 + P412	Protect from sunlight. Do not expose to temperatures exceeding 50 oC/122oF.
P411 + P235	Keep cool.
Disposal
Code	Phrase
P501	Dispose of contents/container to ...
P502	Refer to manufacturer/supplier for information on recovery/recycling

Physical hazards
Code	Phrase
H200	Unstable explosive
H201	Explosive; mass explosion hazard
H202	Explosive; severe projection hazard
H203	Explosive; fire, blast or projection hazard
H204	Fire or projection hazard
H205	May mass explode in fire
H220	Extremely flammable gas
H221	Flammable gas
H222	Extremely flammable aerosol
H223	Flammable aerosol
H224	Extremely flammable liquid and vapour
H225	Highly flammable liquid and vapour
H226	Flammable liquid and vapour
H227	Combustible liquid
H228	Flammable solid
H229	Pressurized container: may burst if heated
H230	May react explosively even in the absence of air
H231	May react explosively even in the absence of air at elevated pressure and/or temperature
H240	Heating may cause an explosion
H241	Heating may cause a fire or explosion
H242	Heating may cause a fire
H250	Catches fire spontaneously if exposed to air
H251	Self-heating; may catch fire
H252	Self-heating in large quantities; may catch fire
H260	In contact with water releases flammable gases which may ignite spontaneously
H261	In contact with water releases flammable gas
H270	May cause or intensify fire; oxidizer
H271	May cause fire or explosion; strong oxidizer
H272	May intensify fire; oxidizer
H280	Contains gas under pressure; may explode if heated
H281	Contains refrigerated gas; may cause cryogenic burns or injury
H290	May be corrosive to metals
Health hazards
Code	Phrase
H300	Fatal if swallowed
H301	Toxic if swallowed
H302	Harmful if swallowed
H303	May be harmful if swallowed